Nan Jin

UCSF Helen Diller Family Comprehensive Cancer Center

Phone: 1-530-***-****

Email: adkqae@r.postjobfree.com

PROFESSIONAL SUMMARY

Eight years of hands-on experience in cancer research with a strong record of publications in peer- reviewed journals (Cancer Cell, Nature communications, Oncogene etc.)

Demonstrated ability to lead and manage diverse projects, including in the areas of kinase inhibitor discovery, drug resistance, metabolism-targeted cancer therapy, the immune mechanism for anti- inflammatory drugs

In depth knowledge of cancer biology with a focus on translational medicine science (basic to clinical)

Active participation in collaborative research using efficient communication skills EDUCATION

Ph.D. in Cancer Biology (2012-2018)

Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, China B.S. in Pharmacy (2008-2012)

East China University of Science and Technology (ECUST), China RESEARCH EXPERIENCE

Head and neck cancer translational research (2018-present) University of California at San Francisco, Postdoctoral Fellow

PIK3CA is the most commonly mutated oncogene in head and neck cancer and the functional significance of 37% of these mutations was previously unknown. All rare PIK3CA mutants found in head and neck cancer were systematically identified in our study and 68.8% of them were activating. We reported a robust clinical response to a PI3K inhibitor (Alpelisib) in a head and neck cancer patient with a rare PIK3CA mutation. Together, our work indicated that head and neck patients with activating rare PIK3CA mutations may benefit from PI3K-targeted therapies.

We previously reported the use of non-steroidal anti-inflammatory drugs, such as Aspirin, associated with enhanced survival in PIK3CA altered head and neck cancer patients based on a retrospective clinical study. I am revealing its mechanism by characterizing the intra-tumor immune cell populations.

I am also currently involved in a collaboration with Quantitative Biosciences Institute at UCSF (Nevan Krogen Lab) to explore the resistance mechanism of Cetuximab, the only targeted therapy approved for treatment of head and neck cancer, by integrating proteomics, phosphor-proteomics and protein- protein interactome with functional genomic CRISPRi screen. Jin N1, Lee M, Keam B, Cho J, Kim H, Ng K, Mills GB, Torosyan H, Jura NZ, Kang H, Kim M, Johnson DE* and Grandis JR*. Therapeutic implications of activating non-canonical PIK3CA mutations in head and neck squamous cell carcinoma. (Nature Medicine. Submitted, 1First author) Swaney DL, Steffen DJ. Wang Z, Park J, Goto Y, Soucheray M, Bhola N, Jin N, Kim K, Zheng F, Zeng Y, Keefe RO, Dollen JV, Bouhaddou M, Kreisberg JF, Kim M, Johnson DE, Grandis JR, Gutkind JS, Ideker T* and Krogan NJ*. A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity (Science. In revision.) Lee M1, Jin N1, Grandis JR* and Johnson DE*. Alterations and molecular targeting of the GSK-3 Regulator, PI3K, in head and neck cancer (BBA-Mol Cell Res., 2020 Jun;1867(6):118679, 1Co-first author) Metabolism-targeted cancer therapy (2014-2018)

One of the biggest hurdles for the development of metabolism-targeted therapies is to identify the responsive tumor subsets. Our work demonstrated that the genetic activation of distinct receptor tyrosine kinases (RTKs) resulted in unique metabolic vulnerabilities, which is to direct the metabolism- targeted drugs to cancer patients bearing RTKs genetic alterations based on the metabolic signatures.

Our work uncovered the novel function of Phosphoglycerate mutase 1 (PGAM1), a glycolytic enzyme was to promote cancer cell migration independent of its metabolic activity. Jin N1, Bi A1, Lan X1, Xu J, Wang X, Liu Y, Wang T, Tang S, Zeng H, Chen Z, Tan M, Ai j, Xie H, Zhang T, Liu D, Huang R, Song Y, Leung E, Yao X, Ding J, Geng M*, Lin S*, Huang M*. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. (Nature Communications., 2019 Sep 12;30(3):459-473, 1Co-first author) Zhang D1, Jin N1, Sun W1, Li X, Liu B, Xie Z, Qu J, Xu J, Yang X, Su Y, Tang S, Han H, Chen D, Ding J, Tan M, Huang M*, Geng M*. Phosphoglycerate Mutase 1 Promotes Cancer Cell Migration Independent of its Metabolic Activity.

(Oncogene., 2017 May 18;36(20):2900-2909., 1Co-first author) Qu J, Sun W, Zhong J, Lv H, Zhu M, Xu J, Jin N, Xie Z, Tan M, Lin S, Geng M, Ding J*, Huang M*. Phosphoglycerate mutase 1 is required for homologous recombination repair via sustaining the stability of CtIP. (The Journal of Cell Biology., 2017 Feb;216(2):409-424.)

Sun W, Xie Z, Liu Y, Zhao D, Wu Z, Zhang D, Lv H, Tang S, Jin N, Jiang H, Tan M, Ding J, Luo C*, Li J*, Huang M*, Geng M*. JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification.

(Cancer Research., 2015 Nov 15;75(22).4923-36.)

Drug resistance (2014-2016)

Histone deacetylase (HDAC) inhibitors demonstrated clinical benefits in subtypes of hematological malignancies, while their efficacy in solid tumors remains uncertain. Our work discovered the activation of LIFR-JAK1-STAT3 signaling centered feedback loop stimulated by HDACs inhibitors, which required bromodomain containing 4 (BRD4), implicating the combination inhibition of HDAC with JAK1 or BRD4. Zeng H1, Qu J1, Jin N1, Xu J, Lin C, Chen Y, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M*, Ding J*, Geng M*. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylases inhibitors in breast cancer. (Cancer Cell., 2016 Sep 12;30(3):459-473, 1Co-first author) INDUSTRY EXPERIENCE (2012-2016)

Servier Laboratories joint program

The combo study of Lucitanib, a multi-kinase inhibitor targeting VEGFR, FGFR etc., and Everolimus (mTOR inhibitor) in gastric and hepatocelluar carcinoma

Greenvalley Pharmaceutical CO., Ltd. joint program Rational design, synthesis and biological screening molecularly ERK-targeted drugs Gao D1, Jin N1, Zhu Y, Wang Y, Wang T, Chen Y, Zhang M, Xiao Q, Huang M, Li Y*. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors. (European Journal of Medicinal Chemistry. EJMECH_113333, 1Co-first author) Li L, Liu F, Jin N, Tang S, Chen Z, Yang X, Ding J, Geng M, Jiang L, Huang M*, Cao J*. Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2).

(Bioorganic & Medicinal Chemistry Letters., 2016 Jun 1;26(11):2600-4.) QUALIFICATIONS

Superb skills in a wide range of in-vitro molecular/cellular assays and in-vivo studies

Expertise in genetic manipulation of cells; siRNA and CRISPR/cas9 based functional genomic approaches

Proficiency in tissue dissociation and multicolor flow cytometry analysis (8+ colors) of immune cell characterization

Hands on experience with mass spectrometry-based technology, such as metabolic flux analysis (MFA) using isotope labeled substrates, cytometry by time-of-flight (CyTOF), and affinity-purification mass spectrometry (APMS)

Excellent project management, data interpretation, troubleshooting and professional writing

Experienced in mentorship, teamwork and external collaborations with scientific communication HONORS & AWARDS

Excellent Paper in 15th National Academic Conference on Clinical and Translational Medicine (2017)

Special Award of Excellent Paper in 17th Annual Meeting of Shanghai Pharmacology Association (2016)

Chinese National Scholarship (2016)

Excellent Students Awards of University of Chinese Academy of Sciences (2014) CONFERENCE & PRESENTATIONS

CCMI External Advisory Committee Meeting / NCI Site Visit, San Francisco, CA. (Poster Presentation, 2020)

NCI Division of Cancer Biology CSBC-PSON Junior Investigators Meeting, Bethesda, Maryland, CA. (Oral Presentation. 2019)

AACR Immune Cell Therapies for Cancer, San Francisco, CA (Poster Presentation. 2019)

AACR Annual Meeting, Washington, D.C. (Poster Presentation. 2017)

National Academic Conference on Clinical and Translational Medicine, China. (Oral Presentation. 2017)

Contact this candidate